Nabsys Inc

Founded in 1980, Amgen is one of the leading companies in the biotechnology industry. The company discovers, develops, manufactures and delivers human therapeutic products. It provides therapeutic services to treat a range of illnesses that includes cancers, kidney diseases and rheumatoid arthritis. Amgen also offers services to treat autoimmune diseases, such as psoriatic arthritis and ankylosing spondylitis. The company works with a team of more than 17,500 staff members. It is affiliated with Biotechnology industry Organization, Healthcare Leadership Council and Pharmaceutical Research manufacturers of America. Amgen conducts research programs related to inflammation, metabolism disorders, osteoporosis, neuroscience, oncology and hematology. Headquartered in Thousand Oaks, Calif., it maintains a location in West Greenwich, R.I.

Celldex Therapeutics is a biopharmaceutical company that applies its Immunotherapy Platform to treat various diseases. Its immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates. Celldex Therapeutics technology platform uses human monoclonal antibodies administered directly to patients to target dendritic cells and macrophages that are key cells in the immune system. Its APC Targeting Technology delivers an antigen that results in more efficient processing than a nontargeted antigen. The company develops various therapeutic human monoclonal antibody products. Its lead programs are for oncology targets. Celldex Therapeutics has two clinical programs under clinical evaluation for the therapy of cancer.

C4 Therapeutics, Inc. is a biotechnology company based in Watertown, MA, specializing in targeted protein degradation. Their innovative approach, known as Targeted Protein Degradation (TPD), aims to develop a new generation of medicines for treating various diseases. Through their TORPEDO platform and focus on target selection, C4 Therapeutics is dedicated to transforming lives by degrading disease-causing proteins. With a strong leadership team, board of directors, and scientific advisory board, C4 Therapeutics is committed to advancing their pipeline of therapies, including CFT7455, CFT1946, and CFT8919. They also collaborate with industry partners such as Roche, Biogen, Betta Merck, and others to further their research and development efforts. At C4 Therapeutics, their values, people, and dedication to scientific progress drive their mission to revolutionize the treatment of diseases through targeted protein degradation.Generated from the website